TRAIL Monoclonal antibody

TRAIL Monoclonal Antibody for WB, IHC, ELISA

Host / Isotype

Mouse / IgG1

Reactivity

Human and More (1)

Applications

WB, IF, IHC, ELISA

Conjugate

Unconjugated

Publications

3

CloneNo.

1B9B4

Cat no : 66756-1-Ig

Synonyms

Apo 2 ligand, Apo 2L, APO2L, CD253, Protein TRAIL, TL2, TNFSF10, TRAIL

---

Validation Data Gallery

• 

  WB analysis of human milk using 66756-1-Ig

  human milk were subjected to SDS PAGE followed by western blot with 66756-1-Ig (TRAIL antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human tonsillitis using 66756-1-Ig

  Immunohistochemical analysis of paraffin-embedded human tonsillitis tissue slide using 66756-1-Ig (TRAIL antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human tonsillitis using 66756-1-Ig

  Immunohistochemical analysis of paraffin-embedded human tonsillitis tissue slide using 66756-1-Ig (TRAIL antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human prostate cancer using 66756-1-Ig

  Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 66756-1-Ig (TRAIL antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human prostate cancer using 66756-1-Ig

  Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 66756-1-Ig (TRAIL antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Tested Applications

• Positive WB detected in: human milk tissue
• Positive IHC detected in: human tonsillitis tissue, human prostate cancer tissue; Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

• Western Blot (WB): WB : 1:500-1:2000
• Immunohistochemistry (IHC): IHC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, Check data in validation data gallery.

Published Applications

• WB: See 1 publications below
• IF: See 1 publications below

Product Information

66756-1-Ig targets TRAIL in WB, IF, IHC, ELISA applications and shows reactivity with Human samples.

• Tested Reactivity: Human
• Cited Reactivity: human
• Host / Isotype: Mouse / IgG1
• Class: Monoclonal
• Type: Antibody
• Immunogen: TRAIL fusion protein Ag25746
• Full Name: tumor necrosis factor (ligand) superfamily, member 10
• Calculated Molecular Weight: 281 aa, 33 kDa
• Observed Molecular Weight: 28-30 kDa
• GenBank Accession Number: BC032722
• Gene Symbol: TRAIL
• Gene ID (NCBI): 8743
• RRID: AB_2882102
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Protein A purification
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

TNFSF10/TRAIL (tumor necrosis factor superfamily member 10) is a typical death ligand expressed on natural killer cells and cytotoxic T lymphocytes. This protein preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues. TNFSF10 induces apoptotic cell death in cancer by binding to its functional death receptors, death receptor (DR) 4 (TNFRSF10A/TRAIL-R1) and DR5 (TNFRSF10B/TRAIL-R2) to activate the extrinsic apoptosis pathway. TRAIL also activates c-Jun N-terminal kinase (MAPK8/JNK) and the transcription factor nuclear factor-κB (NFκB). The binding of this protein to its receptors has been shown to trigger the activation of MAPK8/JNK, caspase 8, and caspase 3.

Publications

Species	Application	Title
human		Adv Healthc Mater; TRAIL-Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582).; Authors - Huan Hou
human	WB	Cancers (Basel); Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib.; Authors - Changhong Ke
human	IF	Front Bioeng Biotechnol; The inhibitory effect of human umbilical cord mesenchymal stem cells expressing anti-HAAH scFv-sTRAIL fusion protein on glioma; Authors - Tian Xue